Thymosin Alpha-1 Side Effects: What the Trials Report, the Immune Questions, and What to Watch

The products this page covers:

At 2 mg/mL, 0.25 mL is 0.5 mg of thymosin alpha-1 per dose (arithmetic from the vial strength, on a U-100 insulin syringe), and a vial holds 20 doses, about four weeks of weekday dosing. Your own directions are set by your physician after reviewing your intake and are printed on the vial. Prices are all-in: medication, physician review, refill management and shipping, with no membership fee. Thymosin alpha-1 is compounded by a PCAB-accredited, FDA-registered US 503A pharmacy. Compounded medications are not FDA approved.

Thymosin alpha-1 is a 28-amino-acid peptide the thymus already makes, cut from a larger precursor called prothymosin alpha. It is not a hormone, a steroid or a growth factor, and it is not an immunosuppressant. It is a signalling peptide that changes how certain immune cells respond: in cell and animal work it increases dendritic-cell signalling and T-cell maturation where those are deficient, and in other settings pushes the response toward regulatory T cells and tolerance.

A synthetic version, under the generic name thymalfasin, has been sold since the 1990s as a branded 1.6 mg injection approved in a number of countries, mainly for hepatitis B and as a vaccine adjuvant. It is not approved in the United States, and a compounded thymosin alpha-1 prescribed in the US carries none of those approvals. But that history means decades of use and a body of randomised trials to read side effects from.

Thymosin alpha-1 has been studied in randomised controlled trials in humans in several disease areas over more than thirty years. None was in healthy adults, and the side-effect picture comes from sick populations.

Across the randomised trials, including the 1,106-patient sepsis trial, adverse-event rates are reported as similar to placebo.

The consistent picture across that work is a compound that is well tolerated. The limit is equally consistent: those populations had hepatitis, sepsis or cancer, and many were already very ill, which makes it harder to see minor side effects against the background of the disease. There are no randomised trials of thymosin alpha-1 in otherwise healthy adults, so there is no measured side-effect table for the way it is most often prescribed.

These are reported clinically, not measured against placebo, so there are no reliable percentages for the compounded injection. The Monday-to-Friday pattern is a common prescriber schedule; the branded product's labelled schedule is 1.6 mg twice weekly, so physicians write it differently and the directions on your vial are the ones to follow. Never change your own dose or schedule.

Thymosin alpha-1 was placed in Category 2 of the FDA's interim 503A bulk drug substances list in 2023. In September 2024 the nominators withdrew the nomination, and the FDA removed it from Category 2 effective 27 September 2024.

On 4 December 2024 the FDA's Pharmacy Compounding Advisory Committee voted 4 to 17 against adding thymosin alpha-1 (free base) and thymosin alpha-1 acetate to the 503A Bulks List. The FDA's briefing stated that the substances were not well characterised physicochemically, that safety information including immunogenicity risk was insufficient, and that there was a lack of evidence of effectiveness for the conditions evaluated. That vote is a recommendation, not a rule. On the FDA's interim list updated 14 May 2026, thymosin alpha-1 does not appear in Category 1, 2 or 3, and the FDA has not issued a final determination.

The immunogenicity point is about the material, not the molecule: an injected peptide that is aggregated or carries impurities could in principle provoke an immune response. That is a reason to care who compounds it. Pepti publishes lot test results at /quality/lab-results.

Thymosin alpha-1 is injected under the skin, into the fat layer, usually in the abdomen or thigh, rotating sites. A small lump that appears as you inject and softens over a day or two is fluid in the tissue; one that appears days later and is warm or spreading needs a same-day message. Technique is in how to inject peptides safely.

The Pen cartridge contains the same medication, dosed in clicks on a reusable injector rather than drawn from a vial. Neither format is clinically better, and the same side effects apply to both.

Vials ship refrigerated with ice packs, with sterile syringes and alcohol prep pads. Beyond-use dating runs from first puncture and is on the label.

• site reactions that are getting worse rather than settling
• any flare of an autoimmune or inflammatory condition
• you start any immunosuppressive treatment, or are scheduled for a transplant
• you are diagnosed with cancer or start cancer treatment
• you are diagnosed with an infection that needs treatment
• you start any new medication, or become pregnant

There is no established interaction list for thymosin alpha-1, which is why the intake asks for every medication you take.

Bloodwork is not required for any Pepti treatment. If your physician wants labs for your care, they'll ask through your account.

They are related only by name. TB-500 is a fragment of thymosin beta-4, studied around tissue repair, with no human randomised trials; clinically it produces mostly injection-site reactions, with some people reporting a brief headache or head-rush after a dose, or tiredness in the first week, and a personal history of cancer is raised at intake. Thymosin alpha-1 has decades of randomised trials reporting adverse events similar to placebo, and its intake questions are immune ones. The FORTIFY Blend carries thymosin alpha-1 with BPC-157, KPV and LL-37, and the points on this page apply to its thymosin alpha-1 component. The wider category is in peptides for immune support.

Thymosin alpha-1's safety record is real and long: randomised trials in hepatitis B, hepatitis C, sepsis and melanoma, the largest a 1,106-patient double-blind trial, all reporting it as well tolerated with adverse events similar to placebo. No withdrawal, rebound or dependence is described in decades of use of the branded product. What the record does not cover is the population that most often asks about it: there are no randomised trials in healthy adults, the compounded schedule differs from the branded one, and the FDA judged the safety information for compounded material, including immunogenicity, insufficient. The general picture is in peptide side effects: what to watch for.

Thymosin alpha-1 cannot be bought legitimately without a prescription. Products sold "for research use only" have no accountable pharmacy behind their identity, purity, sterility or concentration, which is the quality question the FDA raised. The prescription route:

1. Complete a free online intake covering your history, medications, immune conditions and what you want help with.
2. A physician licensed in your state reviews it, usually within 24 hours.
3. If it is appropriate, a PCAB-accredited, FDA-registered US 503A compounding pharmacy prepares it to that prescription. Lot test results are published at /quality/lab-results.
4. It ships refrigerated with ice packs, with sterile syringes and alcohol prep pads, and your directions printed on the vial.
5. Your care team stays reachable for side effects and questions. Refills run every 28 days, one vial per fill.

Pepti is cash-pay and does not bill insurance, and prescribes thymosin alpha-1 in every state except Oklahoma, plus DC The step-by-step page is how to get thymosin alpha-1 prescribed online.